Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 Aug;28(2):299–301. doi: 10.1128/aac.28.2.299

Randomized, double-blind comparison of ceftazidime and moxalactam in complicated urinary tract infections.

E A Horowitz, L C Preheim, T J Safranek, M P Pugsley, C C Sanders, M J Bittner
PMCID: PMC180235  PMID: 3914859

Abstract

Sixty-seven patients with complicated urinary tract infections were randomized in double-blind fashion to ceftazidime or moxalactam (MOX). A total of 54 patients were evaluable, 27 in each group. Patients received 500 mg of antibiotic intravenously every 12 h, except for those with Pseudomonas aeruginosa randomized to MOX who received 2 g intravenously every 12 h. Toxic effects with ceftazidime were experienced by the following number of patients: pain with infusion, one; posttherapy diarrhea, one; liver function test elevations, two; and neutropenia, one. Toxic effects with MOX were experienced by the following number of patients: liver function test elevations, two; and prolonged prothrombin time, one. All resolved. At 1 week posttherapy, bacteriologic results were 74% cured, 11% relapsed, 15% reinfection with ceftazidime and 52% cured, 33% relapsed, and 19% reinfection with MOX. Ceftazidime was effective for infections caused by MOX-resistant P. aeruginosa. P. aeruginosa resistant to MOX and other beta-lactams was isolated from one patient after MOX therapy. Enterococcal reinfection was common in both groups.

Full text

PDF
300

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bauer A. W., Kirby W. M., Sherris J. C., Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966 Apr;45(4):493–496. [PubMed] [Google Scholar]
  2. Cox C. E. A comparison of ceftazidime and tobramycin in the treatment of complicated urinary tract infections. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):47–52. doi: 10.1093/jac/12.suppl_a.47. [DOI] [PubMed] [Google Scholar]
  3. Gleckman R., Crowley M., Natsios G. A. Therapy of recurrent invasive urinary-tract infections of men. N Engl J Med. 1979 Oct 18;301(16):878–880. doi: 10.1056/NEJM197910183011607. [DOI] [PubMed] [Google Scholar]
  4. Gozzard D. I., Geddes A. M., Farrell I. D., Eykyn S. J., Phillips I., Wise R., Brown R. M. Ceftazidime--a new extended-spectrum cephalosporin. Lancet. 1982 May 22;1(8282):1152–1156. doi: 10.1016/s0140-6736(82)92228-0. [DOI] [PubMed] [Google Scholar]
  5. Krieger J. N., Kaiser D. L., Wenzel R. P. Nosocomial urinary tract infections: secular trends, treatment and economics in a university hospital. J Urol. 1983 Jul;130(1):102–106. doi: 10.1016/s0022-5347(17)50980-5. [DOI] [PubMed] [Google Scholar]
  6. Neu H. C. The new beta-lactamase-stable cephalosporins. Ann Intern Med. 1982 Sep;97(3):408–419. doi: 10.7326/0003-4819-97-3-408. [DOI] [PubMed] [Google Scholar]
  7. O'Callaghan C. H., Acred P., Harper P. B., Ryan D. M., Kirby S. M., Harding S. M. GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity. Antimicrob Agents Chemother. 1980 May;17(5):876–883. doi: 10.1128/aac.17.5.876. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Penn R. G., Preheim L. C., Sanders C. C., Giger D. K. Comparison of moxalactam and gentamicin in the treatment of complicated urinary tract infections. Antimicrob Agents Chemother. 1983 Oct;24(4):494–499. doi: 10.1128/aac.24.4.494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Platt R., Polk B. F., Murdock B., Rosner B. Mortality associated with nosocomial urinary-tract infection. N Engl J Med. 1982 Sep 9;307(11):637–642. doi: 10.1056/NEJM198209093071101. [DOI] [PubMed] [Google Scholar]
  10. Preheim L. C., Penn R. G., Sanders C. C., Goering R. V., Giger D. K. Emergence of resistance to beta-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 1982 Dec;22(6):1037–1041. doi: 10.1128/aac.22.6.1037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Sanders C. C. Novel resistance selected by the new expanded-spectrum cephalosporins: a concern. J Infect Dis. 1983 Mar;147(3):585–589. doi: 10.1093/infdis/147.3.585. [DOI] [PubMed] [Google Scholar]
  12. Swabb E. A., Leitz M. A., Pilkiewicz F. G., Sugerman A. A. Pharmacokinetics of the monobactam SQ 26,776 after single intravenous doses in healthy subjects. J Antimicrob Chemother. 1981 Dec;8 (Suppl E):131–140. doi: 10.1093/jac/8.suppl_e.131. [DOI] [PubMed] [Google Scholar]
  13. Yu V. L. Enterococcal superinfection and colonization after therapy with moxalactam, a new broad-spectrum antibiotic. Ann Intern Med. 1981 Jun;94(6):784–785. doi: 10.7326/0003-4819-94-6-784. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES